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Abstract 
Background: Deficient peroxisome proliferator activator receptor-γ coactivator-1α (PGC-1α) 
function is one component of mitochondrial dysfunction in neurodegenerative diseases. 
Current molecular classification of such diseases is based on the predominant protein 
accumulating as intra- or extracellular aggregates. Experimental evidence suggests that 
mitochondrial dysfunction and impaired protein processing are closely interrelated. In vitro 
findings further indicate that PGC-1α dysfunction may contribute to protein misfolding in 
neurodegeneration.  
Objective: To systematically evaluate the neuropathological alterations of mice lacking the 
expression of the full-length PGC-1α protein (FL-PGC-1α) but expressing an N-truncated 
fragment. 
Methods: To assess the pattern of neurodegeneration-related proteins, we performed 
immunostaining for Tau, p-Tau, α-synuclein, amyloid-β, amyloid precursor protein, prion 
protein, FUS, TDP-43 and ubiquitin. Using Hematoxylin and Eosin, Klüver-Barrera and 
Bielschowsky silver stainings and anti-GFAP immunohistochemistry, we performed an 
anatomical mapping to provide a lesion profile. 
Results: The immunohistochemical pattern of neurodegeneration-related proteins did not 
differ between FL-PGC-1α knockout and wild-type animals, and there was a complete lack of 
protein deposits or ubiquitin-positive inclusions. The analysis of neuropathological alterations 
revealed wide-spread vacuolation predominating in the cerebral white matter, caudate-
putamen, thalamus and brainstem, and reactive astrogliosis in the brainstem and cerebellar 
nuclei. This morphological phenotype was thus reminiscent of human mitochondrial 
encephalopathies, especially the Kearns-Sayre syndrome. 
Conclusion: We conclude that the lack of FL-PGC-1α per se is insufficient to recapitulate 
major features of neurodegenerative diseases, but evokes a pathology seen in mitochondrial 
encephalopathies, which makes PGC-1α-deficient mice a valuable model for this yet 
incurable group of diseases. 
Keywords: peroxisome proliferator activator receptor gamma coactivator-1alpha; 
mitochondrial dysfunction; misfolded protein; neurodegeneration; neuropathology; 
mitochondrial encephalopathy; Kearns-Sayre syndrome 
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Introduction 
Mitochondria are membrane-bound organelles in the cytoplasm supposedly originating from 
the endosymbiosis of an ancient aerobic prokaryote with a eukaryotic cell. They provide 
environment for several essential biochemical processes, including the synthesis of adenosine 
triphosphate (ATP), and have a pivotal role in adaptive thermogenesis, intracellular Ca2+ 
homeostasis, cell-cycle regulation, development, aging and cell death. Mitochondrial 
dysfunction, accompanied by subsequent cellular energy imbalance and an overproduction of 
reactive oxygen species (ROS), has been strongly implicated in the pathogenesis of several 
neurological disorders, including the neurodegenerative diseases (NDDs) [1] and the 
primarily childhood-onset mitochondrial encephalopathies [2].  
NDDs, such as Huntington’s disease (HD), Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and amyotrophic lateral sclerosis (ALS), are characterized by progressive loss of 
neurons in particular regions of the central nervous system (CNS), which is accompanied by 
the dysfunctional degradation and subsequent aggregation of misfolded proteins such as 
hyperphosphorylated tau (pTau), amyloid-β (Aβ), α-synuclein, prion protein (PrP), trans-
activation response (TAR) DNA-binding protein (TDP-43) and fused in sarcoma protein 
(FUS). Accordingly, current molecular classification of NDDs is based on the predominant 
protein accumulating as intra- or extracellular aggregates [3]. The defects of both relevant 
degradation pathways – ubiquitin-proteasome system and autophagy – have been associated 
with NDDs [4], and emerging evidence based on neurotoxin-induced models of 
neurodegeneration suggests that mitochondrial dysfunction and impaired protein processing 
are closely interrelated [5-11]. 
The nuclear-encoded metabolic master regulator peroxisome proliferator activator 
receptor-γ (PPARγ) coactivator-1α (PGC-1α) has a key integratory role in the transcriptional 
control of cellular energy metabolism, oxidative stress defense, mitochondrial function and 
biogenesis [12]. PGC-1α directly interacts with various transcriptional regulatory factors such 
as PPARs, estrogen-related receptors (ERRs), forkhead box O (FOXO) 1, Yin-Yang 1, 
myocyte-specific enhancer factor 2C (MEF2C) and, most importantly, nuclear respiratory 
factor (NRF) 1 and 2. This robust activation of nuclear transcriptional factors on the one hand 
leads to the increased expression of several nuclear-encoded mitochondrial respiratory 
complex subunits and a number of mitochondrial factors responsible for mitochondrial DNA 
(mtDNA) replication, transcription and translation, and also for mitochondrial protein import 
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and assembly. On the other hand, PGC-1α activation promotes the transformation of 
glycolytic metabolism towards fatty acid oxidation and gluconeogenesis; furthermore, it 
triggers adaptive thermogenesis via the induction of uncoupling protein 1 (UCP1) [13].  
The contribution of PGC-1α deficiency to neurodegenerative processes is supported by 
numerous experimental data [14]. Complementary to these, deficient PGC-1α axis has been 
reported in HD [15], PD [16] and AD [17] patients. Additionally to impaired mitochondrial 
biogenesis, PGC-1α-deficient neurons exhibit a markedly increased sensitivity against 
mitochondrial oxidative stress, as PGC-1α is required for the recruitment of general 
antioxidant responses [18]. In line with the data linking mitochondrial dysfunction to impaired 
protein processing, recent in vitro studies demonstrated that PGC-1α deficiency may 
contribute to α-synuclein accumulation [19] and the formation of toxic Aβ [17]. 
PGC-1α has recently been demonstrated to undergo an alternative 3’ splicing between 
exons 6 and 7 producing an in-frame stop codon at amino acid 268, which results in a shorter 
but functionally active splice variant of PGC-1α called N-truncated PGC-1α (NT-PGC-1α) 
[20]. Moreover, both splice variants have been shown to have 3-3 distinct isoforms [21], the 
exact roles of which, however, have not yet been fully elucidated. In the past years, two 
independently developed whole-body knockout murine strains of PGC-1α have been 
characterized. Surprisingly, however, despite the well-established contribution of PGC-1α in 
mitochondrial functions, these knockouts are viable and fertile [22, 23], suggesting the 
presence of functional compensatory pathways. The first strain generated by Lin et al. 
represents a complete knockout of PGC-1α [23], displaying no residual expression of any 
fragments of the protein (PGC-1α -/-). The parallel developed knockout strain described by 
Leone et al. [22] lacks the expression of the full-length protein (FL-PGC-1α -/-) but readily 
expresses a slightly shorter form of NT-PGC-1α (amino acids 1-254) denoted as NT-PGC-
1α254, which has very recently been shown to be functionally identical with the complete NT 
splice variant [21]. Notably, both PGC-1α knockout strains were reported to display 
spongiform brain vacuolation predominantly in the caudate-putamen, which first led to the 
conclusion that PGC-1α deficiency may model neurodegeneration. However, a number of 
interesting differences could be observed between the two strains, which include the intact 
thermoregulation, unimpaired hepatic gluconeogenesis and the adult onset obesity seen in FL-
PGC-1α -/- mice. While the presence of functional NT-PGC-1α254 may explain the observed 
metabolic and thermoregulatory differences between the two knockout strains, the apparent 
similarity in the gross neuropathological phenotype and the progressive myopathy observed in 
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FL-PGC-1α -/- mice [22] indicate that the lack of FL-PGC-1α per se results in an 
irreplaceable loss of some aspects of mitochondrial function. 
Based on the concordant data linking mitochondrial dysfunction and PGC-1α 
deficiency to the dysregulation of protein processing and handling, in our present study, we 
performed a systematic neuropathological characterization of adult mice lacking the 
expression of FL-PGC-1α, with special focus on the immunohistochemical pattern of 
neurodegeneration-related proteins.  
In addition to the complete lack of pathological protein aggregation, the 
comprehensive mapping of lesion profiles, comprising spongiform vacuolated lesions and 
astrogliosis, showed that FL-PGC-1α -/- mice evoke a tissue pathology seen in human 
mitochondrial encephalopathies, but do not associate with the pathology seen in adult-onset 
neurodegenerative diseases like HD, PD or AD. 
Materials and methods 
Animals 
FL-PGC-1α -/- mice developed on C57Bl/6J background were generated in Kelly Lab 
(Sanford-Burnham Institute for Medical Research at Lake Nona, Orlando, FL, USA). The 
genetic modification of the animals was carried out as previously described by Leone et al. 
[22]. Briefly, the insertion of a neomycin-based gene targeting construct resulted in a 3’ 
homologous recombination and the duplication of exon 3 between exons 5 and 6 of the 
murine PGC-1α gene, which created a coding region frameshift and a subsequent premature 
termination at amino acid 255. 
15 FL-PGC-1α -/- (8 male, 7 female) and 16 (8 male, 8 female) age-matched wild-type 
C57Bl/6J mice were involved in this study. The animals were housed in cages (maximum 4 
per cages) in standard conditions with 12-12h light-dark cycle and ad libitum access to 
standard pellet food and water. The experiments were performed in accordance with the 
European Communities Council Directive (86/609/EEC) and were approved by the local 
animal care committee. The animals were sacrificed at 30 weeks of age. Brains were removed 
on ice and halved at the midline immediately following decapitation. Half brains were fixed in 
4% paraformaldehyde overnight and kept in 10% glycerol in 4°C until embedding in paraffin.  
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Neuropathology and immunohistochemistry 
4-µm-thick sagittal sections of paraffin-embedded brain halves were evaluated. We 
performed the stainings at two levels, one in the level containing the septal nuclei, the medial 
thalamus and the retroflex fascicle, and one in the level of the caudate-putamen, containing 
also the substantia nigra. In addition to Hematoxylin and Eosin, Klüver-Barrera (Luxol and 
Fast red), and Bielschowsky silver stainings, the following monoclonal antibodies 
(crossreacting with mouse) were used for immunohistochemistry: anti-pTau AT8 
(pS202/pT205, 1:200, Pierce Biotechnology, Rockford, IL, USA), anti-α-synuclein (1:10.000, 
clone 4D6, Signet, Dedham, MA, USA), anti-Aβ (1:50, clone 6F/3D, Dako, Glostrup, 
Denmark), anti-amyloid precursor protein (APP) (1:500, Millipore, Billerica, MA, USA) and 
anti-PrP (6H4, 1:1000, Prionics, Schlieren, Switzerland; epitope 144-152). Furthermore, the 
following polyclonal antibodies were used: anti-ubiquitin (1:1000, Dako, Glostrup, Denmark), 
anti-glial fibrillary acidic protein (GFAP) (1:3000, Dako, Glostrup, Denmark) anti-TDP-43 
(1:100, ProteinTech Group, Chicago, IL, USA), anti-tau (1:100, Dako; cross-reacts with the 
tau-equivalent protein in mouse) and anti-FUS (1:1000, Sigma-Aldrich, St. Louis, MO, USA) 
antibodies. The DAKO EnVision detection kit, peroxidase/DAB, rabbit/mouse (Dako, 
Glostrup, Denmark) was used for visualization of antibody reactions. When applying mouse 
antibodies, we used the M.O.M. kit (Vector Laboratories, Burlingame, CA, USA) to prevent 
the aspecific background staining of endogenous mouse immunoglobulins. As positive 
controls for the immunostaining, we used tissue sections from human AD (pTau and Aβ), PD 
(α-synuclein) and frontotemporal lobar degeneration (FTLD) with TDP-43 or FUS inclusions 
(TDP-43 and FUS) as well as tissue sections from scrapie-infected mice (PrP, RML strain, 
Hamilton, MT, USA).  
Neuropathological alterations (vacuolation and astrogliosis) were semiquantitatively 
evaluated in several anatomical regions (table 1).  Respecting the fact that vacuole-like 
alterations may also develop due to histological preparatory processes, vacuoles were scored 
0–4 as follows (fig. 1a): 0) No vacuoles or scattered vacuole-like alterations but not more than 
1 per visual field at 40x magnification; 1) Scattered vacuole-like alterations but not more than 
3 per visual field at 40x magnification; 2) Mildly vacuolated lesion(s) with less than 10 
vacuoles per visual field at 40x magnification; 3) Moderately vacuolated lesion(s) with less 
than 20 vacuoles per visual field at 40x magnification; 4) Severely vacuolated lesion(s) with 
more than 20 vacuoles per visual field at 40x magnification. Astrogliosis were scored 0-3 as 
follows (fig. 1b): 0) No astrocytes or scattered resting asctrocytes; 1) Cloudy positivity with 
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no signs of reactivation; 2) Moderate astrogliosis with multiple reactive astrocytes in a patchy 
distribution; 3) Severe astrogliosis with abundant reactive astrocytes in a confluent pattern.  
Statistical analysis 
The statistical evaluation of the data was carried out by SPSS Statistics 17.0 software®. 
The cross-tabulation analyses of the discrete variables were performed using Fisher’s exact 
test. In structures large enough to be present in both the paramedian and the lateral sections, 
we performed a statistical analysis for the estimation of difference within the FL-PGC-1α -/- 
animals. A value of p < 0.05 was regarded as significant. Structures with statistically 
significant medio-lateral difference were dealt separately; otherwise, pooled data were used 
for the comparative analysis of FL-PGC-1α -/- and wild-type brain structures. 
Results 
Immunostaining for neurodegeneration-related proteins 
Immunostaining for PrP revealed moderate staining of the neuropil, and for α-
synuclein we observed immunopositivity in presynaptic structures. Anti-APP and anti-
phospho-independent tau antibodies showed cytoplasmic immunoreactivity, while for TDP-
43, FUS, and ubiquitin nuclear staining pattern was observed. All of these were the same in 
wild-type and PGC-1α-deficient animals. Moreover, there was a complete lack of tangle-like 
structures, pretangles, glial or astrocytic tau pathology, extracellular plaques (Aβ or PrP) and 
TDP-43, FUS, or ubiquitin-immunopositive inclusion bodies (nuclear or cytoplasmic) in all 
animals and brain regions (fig. 2). The staining intensity was finely and evenly distributed 
throughout all animals, slices and anatomical regions, indicating the adequate penetration of 
the fixative in all brains examined. 
Lesion profile 
Neuropathological changes in the brains of FL-PGC-1α -/- mice consisted of 
vacuolation, predominantly in the white matter, and reactive astrogliosis. 
Spongiform alterations were present throughout the brain in PGC-1α-deficient mice. 
The caudate-putamen was the most severely affected grey matter structure (fig. 3a), followed 
by the antero-lateral nuclei of the thalamus (reticular and ventral posterolateral area), but 
consistent mild to moderate alterations could be observed in the pontomedullary brainstem, 
the tegmental part of the midbrain, the nucleus accumbens, the globus pallidus, the medial 
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thalamus, the mammillary body, the substantia nigra, the cerebellar nuclei, as well as in the 
olfactory, insular, motor, sensory, postsubicular and also throughout the paramedian cortices 
(table 1). However, vacuolation was lacking in the cerebellar cortex, the tectal midbrain and 
the septal nuclei (not shown). Vacuoles within the cerebral cortex generally predominated in 
the deep cortical layers; furthermore, analysis of cerebral cortices in the lateral sagittal 
sections revealed a preference towards the posterior (visual and sensory) versus the anterior 
(motor, insular and piriform) cortices (Fisher’s exact value = 19.184; p < 0.001). Spongiform 
change in the pontomedullary brainstem was more severe in the paramedian than in the lateral 
sections (Fisher’s exact value = 9.282; p = 0.018). Notably, the hippocampal grey matter (i.e. 
cornu Ammonis (CA) 1-3 and the dentate gyrus) was relatively preserved, with consistent 
vacuolation mainly in the white matter bundles of the lacunosum molecular layer of the CA1, 
as revealed by the Klüver-Barrera staining of the lateral sections (supplementary fig. 1a). 
Similarly, the Klüver-Barrera staining of the caudate-putamen revealed that, besides being 
present in the striatal neuropil, the vacuoles within the caudate-putamen were the most 
abundant in the streaming fibers of the anterior internal capsule (pencil fibers) (supplementary 
fig. 1b). 
In the white matter structures, robust vacuolation was observed in the internal capsule 
(fig. 3a) and the retroflex fascicle, mild to moderate alterations were noted in the cerebellar 
white matter, the fimbria hippocampi, the stria terminalis, the anterior commissure and the 
olfactory tract, while the optic tract remained consistently unaffected. Vacuolation of the 
myelin, which was arranged in chains in the severely affected white matter regions, was not 
associated with the damage of axons (fig. 3b). Indeed, there was a lack of APP-
immunoreactive (not shown) or argyrophilic axonal swellings (fig. 3b), excluding 
morphological evidence of a disturbance in axonal transport in association with neuronal 
damage. 
Prominent reactive gliosis was present in the brainstem and within the cerebellar 
nuclei of FL-PGC-1α -/- mice. This was the most striking in the paramedian sections of the 
pontomedullary brainstem (fig. 3c), while moderate astrogliosis was noted in the midbrain, 
the cerebellar nuclei and the lateral pontomedullary brainstem (supplementary fig. 1c). The 
median predominance of the involvement of the pontomedullary brainstem was statistically 
significant (Fisher’s exact value = 10.758; p = 0.004). No other regions of the brain displayed 
any signs of astrocytic reactivation. Moreover, we did not observe pathological degree of 
vascular proliferation in any examined region (data not shown). 
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Discussion 
The involvement of dysfunctional PGC-1α axis in NDDs has already been 
demonstrated. The PGC-1α-dependent thermoregulatory defect in transgenic HD mice and the 
decreased expression of PGC1-1α and its target genes in human brain and transgenic mice 
were the first to suggest contribution in the pathogenesis of HD [24, 25]. Conversely, PGC-1α 
overexpression in transgenic HD models displayed neuroprotective effects [24, 25]. 
Subsequently, a dysfunctional PGC-1α axis was reported in the skeletal muscle of transgenic 
mice and HD patients [15], and PGC-1α gene polymorphisms were associated with the age at 
onset [26, 27]. In HD, mutant huntingtin protein downregulates PGC-1α both through a direct 
interaction with its promoter [24], and through an indirect effect, mediated by an increased 
extrasynaptic NMDA receptor activity and subsequent deregulation of cyclic AMP response 
element-binding protein (CREB) signaling [28]. According to a recent finding, the expression 
of NT-PGC-1α itself is robustly and consistently altered in human and transgenic HD brains, 
human HD myoblasts and transgenic striatal cells [29]. 
Evidence suggests the pathogenic involvement of PGC-1α in PD as well. Indeed, 
several PGC-1α-responsive genes were found underexpressed in PD patients [16], and 
polymorphisms were also reported to be associated with the age at onset and the risk of 
developing PD [30]. Moreover, PGC-1α-deficient mice exhibit an increased sensitivity 
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity [18], whereas the 
overexpression of PGC-1α protects dopaminergic neurons against rotenone and α-synuclein 
toxicity in vitro [16], and against parkin-deficiency in vivo [31]. Ebrahim et al. further 
demonstrated that PGC-1α deficiency promotes the aggregation of α-synuclein in vitro [19]. 
With regard to AD, Qin et al. reported the inverse correlation of hippocampal PGC-1α 
protein content with the severity of cognitive decline, neuritic plaque pathology and 
hippocampal Aβx-42 burden in AD patients [17]. This group also provided in vitro evidence 
that PGC-1α deficiency might contribute to the accumulation of AD-type Aβ in the brain via 
decreasing the non-amyloidogenic α-secretase activity. 
The knockout strain used in our study lacks the expression FL-PGC-1α, but expresses 
a slightly shorter though functionally identical form of a NT-PGC-1α [21].  Indeed, both NT-
PGC-1α and NT-PGC-1α254 can readily coactivate PPARγ and EERα and upregulate UCP1 
[21], which clearly underlies the intact thermoregulation and UCP1 levels in FL-PGC-1α -/- 
mice [21, 22], and may explain the metabolic differences between PGC-1α -/- and FL-PGC-
1α -/- strains. However, NT isoforms lack the central and C-terminal domains responsible for 
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the activation of NRF1, NRF2, MEF2C and FOXO1. The published alterations in 
mitochondria-related protein expression in FL-PGC-1α -/- mice (i.e. decreased expression of 
cytochrome c, respiratory complex subunits and mitochondrial transcription factor A (TFAM) 
[22]) are in line with the roles of NRFs in mitochondrial function, and correspond to the 
observation that NT-PGC-1α is unable to induce cytochrome c expression in PGC-1α -/- cells 
[21].  
Based on the evidences suggesting that mitochondrial dysfunction and impaired 
protein processing are interrelated, together with the in vitro findings associating PGC-1α 
deficiency with protein accumulation [17, 19], we hypothesized that the ablation of FL-PGC-
1α could evoke the accumulation of neurodegeneration-related proteins in vivo. This concept 
seemed feasible since disturbances in protein processing systems and formation of aggregates 
have already been demonstrated in rodents without a transgenic background for 
neurodegeneration-associated proteins (i.e. neurotoxin models [9-11], aged animals [32]). 
However, our systematic immunohistochemical analysis revealed no protein depositions; 
indeed, there was a complete lack of tangle-like structures, extracellular plaques and 
ubiquitin-immunopositive inclusion bodies throughout the brains, and the pattern of 
immunoreactivity was similar in FL-PGC-1α -/- and wild-type animals (fig. 2). These results 
indicate that despite its widely established contribution in NDDs, the absence of FL-PGC-1α 
per se has no major influence on protein processing in adult mice. This suggests a more 
complex scenario for the interaction of mitochondrial dysfunction and protein aggregation in 
NDDs, and is consistent with the finding that PGC-1α deficiency is not associated with a 
gross disturbance of autophagy within the CNS [33]. However, we cannot exclude the 
supplementary effect of NT-PGC1α254 in this context, which question could be answered by 
studying the PGC-1α -/- mice in a similar immunohistochemical paradigm.  
Mitochondrial malfunction is the primary etiological factor in a group of sporadic or 
inherited CNS diseases, collectively termed mitochondrial encephalopathies. The underlying 
genetic alterations can affect either the mtDNA or nDNA. Although the distribution of the 
neuropathological alterations is characteristic to a particular syndrome, mitochondrial 
encephalopathies show various degrees of spongiform vacuolation (in particular regions with 
preserved neurons giving the characteristic appearance of “pseudonecrosis”), reactive 
astrogliosis and, less generally, pathological capillary proliferation (table 2). 
The continuous attempts to create animal models for such diseases have been facing 
difficulties. Indeed, most of the developed genetic modifications result in embryonic or early 
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postnatal lethality (e.g. knockouts of CREB [34], ERRγ [35], NRF1 [36], NRF2 [37], TFAM 
[38], mtDNA polymerase γ 1 (POLG1) [39], optic atrophy 1 (OPA1) [40] and synthesis of 
cytochrome c oxidase 2 (SCO2) [41]), whereas a great proportion of viable strains, 
surprisingly, exhibit no neuropathology (e.g. knockouts of adenine nucleotide translocator 1 
(ANT1) [42], PPARγ [43], ERRα [44] and SURF1 [45]; Twinkle mutant ‘Deletor’ mice [46] 
and ΔmtDNA Mito-Mice [47]). To our knowledge, murine knockouts of apoptosis inducing 
factor (AIF) [48, 49], superoxide dismutase 2 (SOD2) [50], thymidine phosphorylase and 
uridine phosphorylase (TP/UP) [51] and NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 4 (NDUFS4) [52] are the only ones that display a neuropathology resembling that of 
human mitochondrial encephalopathies (table 2).  
In the present study, we characterized the lesion profile of 30-week old FL-PGC-1α -/- 
mice, which age has not been previously characterized neurohistologically in PGC-1α-
deficient mice. The neuropathological findings consisted of widespread spongiform 
vacuolation and circumscribed astrogliosis, whereas vascular proliferation was absent. The 
most striking spongiform alterations were observed in the long white matter bundles of the 
internal capsule and the retroflex fascicle. The most severely affected grey matter regions 
included the thalamus and the caudate-putamen; however, myelin staining revealed the 
massive involvement of the pencil fibers streaming across the caudate-putamen, indicating 
that the abundant vacuolation in this region is at least in part attributable to myelin 
degeneration. The whole forebrain was free of gliosis, which contrasted with the robust and 
confluent astrogliotic reaction in the central pontomedullary brainstem, and the patchy 
reactions in the midbrain and the cerebellar nuclei. Collectively, this pattern is highly 
reminiscent of human mitochondrial spongiform encephalopathies, particularly of KSS and, 
in some aspects, LS (table 2). This impression was further supported by the ovoid shape and 
unidirectional longitudinal axes of the vacuoles in the white matter, the deep occipito-parietal 
preference of the cortical vacuoles, the median predominance of brainstem involvement, 
along with the preservation of axons in the vacuolated fibers as revealed by the lack of APP-
immunopositive and argyrophylic axonal swellings. The sparing of axons contrasts the 
concept proposed by Lin et al. during the characterization of the PGC-1α -/- strain, suggesting 
that the spongiform lesions in the caudate-putamen might arise from axonal degeneration 
[23]. This concept was partially confirmed by a later work of this group, demonstrating that 
neuron-specific knockouts of PGC-1α also exhibit striatal and cortical vacuolation; however, 
with apparently less severity than the whole-body knockouts [33]. Our observations allow us 
to presume that spongy vacuolation in the FL-PGC-1α -/- model may primarily share the 
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etiology of the status spongiosus seen in mitochondrial encephalopathies, in which myelin 
vacuoles are proposed to be attributable to mitochondrial dysfunction in oligodendrocytes, 
whereas grey matter vacuoles are presumed to develop due to the failure of ATP-dependent 
ion transporters in astrocytic membranes [53].  
In their comprehensive study characterizing the PGC-1α -/- strain, Lin et al. reported 
the presence of GFAP-immunopositive astrocytes in the vicinity of the vacuoles within the 
caudate-putamen, which has frequently been interpreted as a direct indicative of striatal 
neurodegeneration, turning the attention to the contribution of PGC-1α to NDDs, especially to 
HD. It must be noted, however, that no reports have yet provided direct evidence of neuronal 
loss in PGC-1α-deficient mice. In the strain examined in this study, the region of the caudate-
putamen indeed displayed some slight GFAP positivity, suggestive of resident astroglia in the 
striatal white matter. However, the pattern of immunoreactivity and the appearance of 
astrocytes did not differ between FL-PGC-1α -/- and wild-type animals. This pattern contrasts 
the massive reactive (i.e. hypertrophic and hyperplastic) astrogliosis in the brainstem and 
cerebellar nuclei of PGC-1α-deficient mice used in our study.  
Our finding that the neuroanatomical pattern of the lesions in this model overlaps with 
multiple human mitochondrial encephalopathies is not that surprising, considering that FL-
PGC-1α contributes to the proper functioning of several downstream proteins which 
practically cover all levels of mitochondrial functioning that have been associated with 
mitochondrial diseases [2]. More surprisingly, PGC-1α-deficient mice are not only free of 
embryonic lethality, but they have normal longevity and acceptable reproduction [22, 23], 
suggesting the existence of potent complementary pathways, probably within the PGC family 
itself. It is possible that the presence of intact PGC-1β and PGC-1-related coactivator (PRC) 
is sufficient to maintain an acceptable level of mitochondrial function, as both possess 
functional domains capable of interacting with nuclear hormone receptors and NRFs [54, 55]. 
This may at least in part explain the apparent discrepancy between the suggested roles of 
PGC-1α in mitochondrial physiology and the observed viable phenotypes of the knockouts. 
Indeed, the directly upstream CREB, and a number of downstream factors (ERRγ, NRF1, 
NRF2, TFAM and POLG1) were found indispensable for embryonic or early postnatal 
development. On the other hand, the murine knockouts of the directly coactivated PPARγ and 
the PGC-1α-dependent ANT1 are viable, but display no neuropathological alterations. The 
most closely reminiscent brain pathology of that observed in this study was reported in the 
murine knockout of SOD2 (also downstream of PGC-1α), indicating that oxidative damage 
may play an important role in the development of the spongiform leukoencephalopathy. 
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Although the lifespan of the SOD2 null model can be somewhat increased by antioxidant 
protection, these animals die within the first 3–4 weeks [50]. We suggest that PGC-1α-
deficient mice with their normal lifespan and measurable neurological symptoms may 
represent a useful animal model to investigate the therapeutic potential of candidates in 
halting the progression of mitochondrial diseases. Our findings also suggest that 
polymorphisms in the PGC-1α gene might be valuable targets of investigation in 
mitochondrial diseases with unidentified genetic origin, and correspond to the notion that the 
activation of PGC-1α axis may be of therapeutic benefit in mitochondrial diseases [56, 57]. 
We conclude that mitochondrial dysfunction due to the lack of FL-PGC-1α per se is 
unable to recapitulate major features of NDDs with regard to impaired protein processing and 
the anatomical pattern of reactive astrogliosis in adult mice. Specifying the nature and 
distribution of the neuropathological alterations in FL-PGC-1α -/- mice, we propose that those 
are reminiscent of human mitochondrial encephalopathies, which makes PGC-1α-deficient 
mice an appropriate and viable animal model for this, yet incurable, group of diseases. 
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Table 1. Lesion profile in the brains of FL-PGC-1α -/- mice. 
Comprehensive mapping of lesion profile in FL-PGC-1α -/- animals, demonstrating the 
typical degree of involvement of an anatomical region in the spongiform vacuolation and 
reactive astrogliosis. The differences between FL-PGC-1α -/- and wild-type animals are 




Typical degree of 
vacuolation Region Mean p-value 
Mild 
cerebellar white matter  1.833 < 0.001 
pontomedullary brainstem l * 1.923    0.005 
substantia nigra 1.375    0.004 
hippocampus m 1.133    0.006 
hippocampus l 1.933 < 0.001 
fimbria hippocampi 1.182    0.007 
Moderate 
cerebellar nuclei * 2.150 < 0.001 
pontomedullary brainstem m ** 2.933 < 0.001 
midbrain * 2.571 < 0.001 
nucleus accumbens 2.600 < 0.001 
globus pallidus 2.692 < 0.001 
mammillary body 2.143 < 0.001 
cerebral cortex 2.305 < 0.001 
thalamus m 2.067 < 0.001 
anterior commissure 2.533 < 0.001 
stria terminalis 2.786 < 0.001 
olfactory tract 2.071 < 0.001 
Severe  
caudate-putamen 4.000 < 0.001 
thalamus l 3.533 < 0.001 
internal capsule 3.615 < 0.001 
retroflex fascicle 4.000 < 0.001 
l lateral section 
m paramedian section 
* accompanied by moderate astrogliotic reaction 
** accompanied by severe astrogliotic reaction. 
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Table 2. Comparative summary of the typical neuropathological findings and their 
distribution in human mitochondrial spongiform encephalopathies and their most reminiscent 
murine models. 
Abbreviations: AIF, apoptosis inducing factor; FL-PGC-1α -/-, knockout for the full-length 
peroxisome proliferator activator receptor gamma coactivator-1alpha protein; KSS, Kearns-
Sayre syndrome; LHON, Leber’s hereditary optic neuropathy; LS, Leigh syndrome; MELAS, 
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes; MERRF, 
myoclonic epilepsy with ragged-red fibers; NDUSF4, NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 4; SOD2, superoxide dismutase 2; TP/UP, thymidine phosphorylase and 
uridine phosphorylase; WM, white matter; +, present; -, absent. 
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Fig. 1. Representative images corresponding to the semiquantitative scores used to evaluate 
vacuolation (a) and astrogliosis (b). 
Bar in a represents 20 µm. 
Abbreviations: H&E, Hematoxylin and Eosin; GFAP, glial fibrillary acidic protein. 
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Fig. 2. The absence of FL-PGC-1α expression is not associated with the accumulation of 
neurodegeneration-related proteins in adult mice. 
Immunostaining for prion protein (PrP), α-synuclein (a-Syn), amyloid precursor protein 
(APP), amyloid-beta (A-beta), Tau, phosphorylated Tau (pTau), TDP-43, FUS, and ubiquitin 
(Ubi) in various anatomical regions in wild-type (WT) and FL-PGC-1α -/- (PGC-1α) animals. 
The representative images demonstrate lack of pathological protein aggregation and inclusion 
body formation throughout the brain of mature FL-PGC-1α -/- mice. 
Bar represents 50 µm for the images of PrP, a-Syn, A-beta, and ubiquitin; 20 µm for APP; and 
7.5 µm for Tau, pTau, TDP-43, and FUS. 
Fig. 3. Lesion profile in the brains of FL-PGC-1α -/- mice is reminiscent of human 
mitochondrial encephalopathies. 
(a) Hematoxylin and Eosin (H&E) staining in different anatomical regions in wild-type (WT) 
and FL-PGC-1α -/- (PGC-1α) animals, demonstrating prominent vacuolation in the caudate-
putamen and the internal capsule in PGC-1α-deficient animals. (b) Vacuolation in the myelin 
(as shown by Klüver-Barrera staining on the left) exhibits chain-like appearance (as 
exemplified by the lower image of the retroflex fascicle) and is associated with relatively 
preserved axons, pushed towards the edge of the vacuoles (as shown by Bielschowsky silver 
staining on the right). (c) Immunostaining for glial fibrillary acidic protein (GFAP) in 
different anatomical regions in wild-type (WT) and FL-PGC-1α -/- animals, showing reactive 
astrogliosis in the brainstem regions.	  Bar in A represents 75 µm for the images of the caudate-
putamen and internal capsule in a and c; 125 µm for the brainstem in c; and 10 and 5 µm for b 
upper and lower panel, respectively. 
